Key Takeaways
- High-profile counterfeit medicine cases—from the 2019 Kentucky SURGICEL incident to counterfeit HIV drugs and Ozempic—expose vulnerabilities in the US healthcare supply chain, especially via unauthorized “gray market” channels.
- Criminal networks exploit forged documentation, fake packaging, and corrupt distributors to infiltrate regulated supply chains with dangerous products.
- Despite strict regulations such as the DSCSA, supply chain security ultimately depends on constant vigilance and strict procurement from authorized sellers.
What has become a landmark case in the annals of anticounterfeiting in the life sciences industry—one a judge described as “horrific”—began in 2019 with a neurosurgeon in an operating room at the University of Kentucky. The surgeon noticed that a medical device he had used many times before didn’t quite feel right. He was about to implant that device, an absorbable hemostat meant to control bleeding, into a patient’s body. But he stopped, because the device didn’t have the same tactile feel or texture that he was accustomed to. He rejected the device, which then led to a quality complaint to the manufacturer.
The chain of events that followed this initial “complaint” in Kentucky spanned approximately three years, involved extensive international investigations, numerous legal proceedings, and ultimately led to multi-million dollar judgments against multiple parties, as well as jail time for at least one individual involved in the major counterfeiting ring that was exposed.1
Of course, this case raised many, many questions. Still, the big question was, “How did that non-sterile, potentially deadly, counterfeit product get there, in the hands of a surgeon in an operating room within the regulated US healthcare supply chain?” Unfortunately, we know that bad actors motivated by profit and with no regard for the personal harm and general havoc they wreak will find a way to break in. “Locks are for honest people,” as the saying goes.
In our increasingly complex healthcare supply chains, there will always be weak links that bad actors will target and attempt to exploit to their advantage. While we don’t have space here to address all the potential weak points, I’d like to focus on what is clearly the most exploited pathway we see and the one that factored into the University of Kentucky case, as well as many others. That is the risk of acquiring medicines and healthcare products from the secondary or gray market, particularly through unauthorized sellers and channels.2 The following cases underscore the importance of diligence and vigilance in our procurement processes.
The Kentucky case involved a product called SURGICEL, manufactured by Johnson & Johnson’s Ethicon division. The investigation revealed that the hospital had acquired the product from an unauthorized gray market distributor in Florida, via a supply chain linked to illicit traders in Dubai and Delhi. The original source of the counterfeits in Delhi, who sold at least 4,000 units, was producing the products by hand in his non-sterile apartment using run-of-the-mill surgical gauze and fake packaging. As is typical in such cases, the buyers were deceived by counterfeit pedigree documents and false assurances from the sellers.